TRT via telehealth in California: what the science supports

What did @socalurologyinstitute actually say?

The account is advertising virtual testosterone replacement therapy (TRT) consultations for California residents. The clinic claims 30 years of experience treating men for low testosterone, positions itself against competitors run by nurse practitioners, and says patients are seen by a "board-certified urologist remotely." The pitch includes a price point: "no more than $250 for a quarter, four times a year." That comes out to $1,000 annually for quarterly blood test reviews, prostate monitoring, fertility guidance, and skin issue management. This is a straightforward marketing video, not a clinical education piece, and it should be evaluated as such.

The claims are specific enough to check. Thirty years of experience is verifiable in principle. The board-certification claim is checkable through the American Board of Urology. The $250/quarter pricing is concrete. And the scope of services described, covering prostate, fertility, and dermatological side effects, is either standard TRT practice or it isn't.

Does the science back this up?

The underlying case for physician-supervised TRT is solid. Where this video gets things right is in the implicit argument that TRT requires real medical oversight, not just a questionnaire and a shipping label.

The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) was the largest cardiovascular safety study of TRT to date, enrolling over 5,200 men. It found no significant increase in major adverse cardiovascular events with testosterone therapy in men with hypogonadism and pre-existing or high cardiovascular risk. That is reassuring, but the trial also underscores why monitoring matters: testosterone use did increase rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the treatment arm. Those are exactly the kinds of issues that quarterly blood work and urologist oversight are designed to catch.

Monitoring hematocrit, PSA, and lipid panels during TRT is supported by the 2018 American Urological Association (Mulhall et al., Journal of Urology) guidelines. The claim that a urologist is better positioned than a nurse practitioner to evaluate prostate-specific issues is debatable in scope but not unreasonable in principle for higher-complexity cases.

What did they get wrong (or right)?

They got more right than wrong here, which is worth acknowledging. The emphasis on blood test oversight, prostate monitoring, and fertility awareness reflects actual standard-of-care recommendations. TRT can suppress endogenous testosterone production and impair spermatogenesis, which is why fertility counseling before starting is genuinely important (Ramasamy et al., 2014, Fertility and Sterility).

The skin issues reference is also legitimate. Acne and oily skin are documented side effects of exogenous testosterone, more common with injections than gels, and worth flagging during consultations.

Where the video is weakest is in the implicit claim that seeing a urologist remotely is categorically superior to other telehealth providers. That depends entirely on the individual urologist, the quality of the intake process, and what labs they actually require. "Board-certified urologist" is a credential, not a guarantee of quality. The framing also nudges patients away from nurse practitioners in a way that overstates the complexity gap for routine, stable TRT cases. NPs with hormone specialization manage TRT competently every day.

The $250/quarter figure also raises a question the video does not answer: does that include labs? Because if labs are billed separately, the real cost is substantially higher.

What should you actually know?

If you are considering TRT, the provider credential matters less than the intake protocol. Before prescribing testosterone, any responsible clinic should require total testosterone drawn in the morning on at least two separate occasions, LH and FSH to differentiate primary from secondary hypogonadism, a complete metabolic panel, hematocrit, PSA if you are over 40, and a discussion of fertility intentions. That is the AUA standard, not a premium add-on.

Virtual TRT is legal in California and can be appropriate for many men. But telehealth has also enabled a wave of clinics that optimize for conversion, not care. Questions to ask any provider: Do they require two confirmatory testosterone draws? Will they withhold treatment if your levels are borderline? Do they have a protocol for managing elevated hematocrit? If the answers are vague, keep looking.

The TRAVERSE trial data gave TRT a relative cardiovascular clearance, but it was not a blanket green light. Men with recent cardiac events, untreated sleep apnea, or active prostate cancer concerns need more than a telehealth consult before starting therapy.

Bottom line on this video

This is an advertisement, and it reads like one. But the underlying clinical points about monitoring, prostate awareness, and fertility counseling are not wrong. The credential flexing and NP dismissal are oversimplified. Anyone choosing a TRT provider, remote or in-person, should evaluate the protocol, not just the title of the person reviewing it.